31.03.2023 - FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024WALTHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) - ...